查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613213

危急性肢體缺血治療市場：依治療類型、最終用戶分類 - 全球預測 2025-2030

Critical Limb Ischemia Treatment Market by Treatment Type (Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy), End-Use (Home Health Care, Hospitals, Outpatient Surgical Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

危急性肢體缺血治療市場2023年估值為41.1億美元，預計到2024年將達到44.6億美元，複合年成長率為8.84%，到2030年將達到74.5億美元。

危急性肢體缺血(CLI) 是一種嚴重的動脈阻塞，會顯著減少流向肢體的血流量，如果不治療，有截肢的風險。由於周邊動脈疾病和糖尿病等慢性疾病的高盛行率，CLI 治療對於改善患者預後和生活品質至關重要。其應用範圍從外科手術（例如旁路移植術和動脈內膜切除術）到非手術方法（包括血管成形術）和新的基於細胞的治療方法。最終用途範圍涵蓋醫院、門診醫療中心和血管專科診所，反映了有效治療所需的多學科方法。全球人口老化、糖尿病盛行率上升以及醫療技術進步推動了市場成長。然而，發展中地區治療費用高、醫療基礎設施不足等因素帶來了挑戰。監管障礙和加強臨床試驗通訊協定的需求也阻礙了市場的進步。主要的潛在機會在於微創治療和個人化醫療方法的開發，生物可吸收支架和幹細胞療法等創新顯示出前景。生物技術公司和研究機構之間的策略聯盟可以促進創新並加強市場准入。重要的是要專注於為服務不足的市場開發經濟上可行的解決方案。患者和初級保健提供者對早期 CLI 症狀缺乏認知也會導致治療延誤。市場相關人員必須注重教育工作，以傳播理解並促進早期診斷。有許多機會利用數位醫療技術（例如遠端醫療和人工智慧診斷工具）來提高患者監測和治療效果。未來，基因組學的進步以及人工智慧與個人化治療計劃的整合將帶來顯著的成長途徑。儘管面臨挑戰，在持續研究和以患者為中心的推動下，CLI 治療市場有望取得重大進展。

主要市場統計
基準年[2023] 41.1億美元
預測年份 [2024] 44.6億美元
預測年份 [2030] 74.5億美元
複合年成長率（%） 8.84%

市場動態：快速發展的危急性肢體缺血治療市場的關鍵市場洞察

供需的動態交互作用正在改變危急性肢體缺血治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 糖尿病和肥胖症盛行率不斷增加
    • 微創手術與再生醫學的創新
    • 提高患者和臨床醫生對早期診斷和治療方案的認知
  • 市場限制因素
    • 併發症的風險
  • 市場機會
    • 幹細胞療法和基因療法的創新
    • 機器人手術和混合手術室的進展
  • 市場挑戰
    • 與先進治療方法相關的高成本

波特五力：駕馭危急性肢體缺血治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解危急性肢體缺血治療市場的外在影響

外部宏觀環境因素在塑造危急性肢體缺血治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解危急性肢體缺血治療市場的競爭狀況

對危急性肢體缺血治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣危急性肢體缺血治療市場供應商的績效評估

FPNV 定位矩陣是評估危急性肢體缺血治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了危急性肢體缺血治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對危急性肢體缺血治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和肥胖症增加
      • 微創手術與再生醫學的創新
      • 提高患者和醫生對早期診斷和治療方案的認知
    • 抑制因素
      • 手術併發症的風險
    • 機會
      • 幹細胞和基因治療的創新
      • 機器人手術和混合手術室的進展
    • 任務
      • 與先進治療方法相關的高成本
  • 市場區隔分析
    • 治療類型：採用血管成形術及置入術作為微創手術
    • 最終用途：醫院在 CLI 患者的診斷、治療和緊急護理中的重要性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的危急性肢體缺血治療市場

  • 血管成形術和置入術
  • 切除術
  • 高壓氧氣療法
  • 藥物治療
  • 外科搭橋手術

第7章危急性肢體缺血治療市場：依最終用途

  • 居家醫療
  • 醫院
  • 門診手術中心
  • 血管專科門診
  • 創傷護理中心

第8章美洲危急性肢體缺血治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區危急性肢體缺血治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東、非洲危急性肢體缺血治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 雅培 Esprit BTK 系統先進治療嚴重四肢癱瘓
    • RimFlow 系統為面臨截肢風險的嚴重周邊動脈疾病患者帶來新希望
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Ambulero Inc
  • Amgen Inc.
  • Antidote Therapeutics Inc
  • Athersys Inc
  • Boston Scientific Corporation
  • Caladrius Biosciences Inc
  • Cardiovascular Systems, Inc.
  • Cesca Therapeutics Inc.
  • Constant Therapeutics LLC
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • Gurus BioPharm Inc
  • Helixmith Co Ltd
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • ImmuneCyte Inc
  • Ixaka Ltd
  • LimFlow SA
  • Lisata Therapeutics
  • Medtronic plc
  • Micro Medical Solutions
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Rexgenero Ltd.
  • Sanofi SA
  • Stempeutics Research Pvt Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-6B0EA07975A2

The Critical Limb Ischemia Treatment Market was valued at USD 4.11 billion in 2023, expected to reach USD 4.46 billion in 2024, and is projected to grow at a CAGR of 8.84%, to USD 7.45 billion by 2030.

Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which significantly reduces blood flow to the extremities and poses a risk of amputation if untreated. Necessitated by the high prevalence of peripheral arterial disease and associated chronic conditions like diabetes, CLI treatment is vital for enhancing patient outcomes and quality of life. Applications range from surgical interventions, such as bypass grafting and endarterectomy, to non-surgical methods including angioplasty, and emerging cell-based therapies. The end-use scope spans hospitals, ambulatory care centers, and specialized vascular clinics, reflecting the multidisciplinary approach required for effective treatment. Market growth is driven by an aging global population, increasing incidence of diabetes, and advancements in medical technologies. However, factors like high treatment costs and inadequate healthcare infrastructure in developing regions present challenges. Regulatory hurdles and the need for enhanced clinical trial protocols also impede market progress. Key potential opportunities lie in the development of minimally invasive treatments and personalized medicine approaches; innovations like bioresorbable scaffolds and stem cell therapies show promise. Strategic collaborations between biotech firms and research institutions can expedite innovation and enhance market entry. Emphasis on developing economically viable solutions for underserved markets is crucial. Limitations also stem from a lack of awareness among patients and primary care providers about early-stage CLI symptoms, which delays treatment. Market players must focus on educational initiatives to broaden understanding and foster early diagnosis. Opportunities abound in leveraging digital health technologies, including telemedicine and AI-driven diagnostic tools, which enhance patient monitoring and treatment efficacy. Looking forward, advancements in genomics and the integration of AI in personalized treatment plans represent substantial avenues for growth. Despite its challenges, the CLI treatment market is poised for significant advancements fueled by ongoing research and a patient-centric focus.

KEY MARKET STATISTICS
Base Year [2023] USD 4.11 billion
Estimated Year [2024] USD 4.46 billion
Forecast Year [2030] USD 7.45 billion
CAGR (%) 8.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Limb Ischemia Treatment Market

The Critical Limb Ischemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes and obesity
    • Innovations in minimally invasive procedures and regenerative medicine
    • Increased patient and clinician awareness about early diagnosis and treatment options
  • Market Restraints
    • Risk of procedural complications
  • Market Opportunities
    • Innovations in stem cell therapy and gene therapy
    • Advances in robotic surgery and hybrid operating rooms
  • Market Challenges
    • High costs associated with advanced treatment modalities

Porter's Five Forces: A Strategic Tool for Navigating the Critical Limb Ischemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Limb Ischemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Limb Ischemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Limb Ischemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Limb Ischemia Treatment Market

A detailed market share analysis in the Critical Limb Ischemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Limb Ischemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Limb Ischemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Limb Ischemia Treatment Market

A strategic analysis of the Critical Limb Ischemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Limb Ischemia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambulero Inc, Amgen Inc., Antidote Therapeutics Inc, Athersys Inc, Boston Scientific Corporation, Caladrius Biosciences Inc, Cardiovascular Systems, Inc., Cesca Therapeutics Inc., Constant Therapeutics LLC, Cynata Therapeutics Ltd, Eli Lilly and Company, Gurus BioPharm Inc, Helixmith Co Ltd, Hemostemix Inc, ID Pharma Co Ltd, ImmuneCyte Inc, Ixaka Ltd, LimFlow SA, Lisata Therapeutics, Medtronic plc, Micro Medical Solutions, Novartis AG, Pluristem Therapeutics Inc., Rexgenero Ltd., Sanofi S.A., Stempeutics Research Pvt Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Critical Limb Ischemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy, Medication, and Surgical Bypass.
  • Based on End-Use, market is studied across Home Health Care, Hospitals, Outpatient Surgical Centers, Specialized Vascular Clinics, and Wound Care Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and obesity
      • 5.1.1.2. Innovations in minimally invasive procedures and regenerative medicine
      • 5.1.1.3. Increased patient and clinician awareness about early diagnosis and treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of procedural complications
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in stem cell therapy and gene therapy
      • 5.1.3.2. Advances in robotic surgery and hybrid operating rooms
    • 5.1.4. Challenges
      • 5.1.4.1. High costs associated with advanced treatment modalities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Adoption of angioplasty and stenting as minimally invasive procedures
    • 5.2.2. End-Use: Importance of hospitals in the diagnosis, treatment, and emergency care of CLI patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Limb Ischemia Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Angioplasty & Stenting
  • 6.3. Endarterectomy
  • 6.4. Hyperbaric Oxygen Therapy
  • 6.5. Medication
  • 6.6. Surgical Bypass

7. Critical Limb Ischemia Treatment Market, by End-Use

  • 7.1. Introduction
  • 7.2. Home Health Care
  • 7.3. Hospitals
  • 7.4. Outpatient Surgical Centers
  • 7.5. Specialized Vascular Clinics
  • 7.6. Wound Care Centers

8. Americas Critical Limb Ischemia Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Limb Ischemia Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Limb Ischemia Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Advanced Treatment for Critical Limb-Threatening Ischemia with Abbott's Esprit BTK System
    • 11.3.2. LimFlow System Offers New Hope for Severe Peripheral Artery Disease Patients Facing Amputation
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Ambulero Inc
  • 3. Amgen Inc.
  • 4. Antidote Therapeutics Inc
  • 5. Athersys Inc
  • 6. Boston Scientific Corporation
  • 7. Caladrius Biosciences Inc
  • 8. Cardiovascular Systems, Inc.
  • 9. Cesca Therapeutics Inc.
  • 10. Constant Therapeutics LLC
  • 11. Cynata Therapeutics Ltd
  • 12. Eli Lilly and Company
  • 13. Gurus BioPharm Inc
  • 14. Helixmith Co Ltd
  • 15. Hemostemix Inc
  • 16. ID Pharma Co Ltd
  • 17. ImmuneCyte Inc
  • 18. Ixaka Ltd
  • 19. LimFlow SA
  • 20. Lisata Therapeutics
  • 21. Medtronic plc
  • 22. Micro Medical Solutions
  • 23. Novartis AG
  • 24. Pluristem Therapeutics Inc.
  • 25. Rexgenero Ltd.
  • 26. Sanofi S.A.
  • 27. Stempeutics Research Pvt Ltd.
  • 28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL LIMB ISCHEMIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY & STENTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL BYPASS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOME HEALTH CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALIZED VASCULAR CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023